PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.
Saved in:
| Title: | PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. |
|---|---|
| Authors: | Abdulla M; Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden., Alexsson A; Clinical Genomics Uppsala, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Sundström C; Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden., Ladenvall C; Clinical Genomics Uppsala, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Mansouri L; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Lindskog C; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Berglund M; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Cavelier L; Clinical Genomics Uppsala, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Enblad G; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Hollander P; Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden., Amini RM; Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden. |
| Source: | Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2021 Apr; Vol. 60 (4), pp. 531-538. Date of Electronic Publication: 2021 Feb 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1651-226X |
|---|---|
| DOI: | 10.1080/0284186X.2021.1881161 |
